Apellis Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Apellis Pharmaceuticals, Inc.
While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.
The blockbuster-tipped eye therapy Syfovre has hit safety doubts and Apellis is streamlining to give more support to the drug’s global launch.
Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.
Pink Sheet analysis finds big jump in the share of novel approvals that received PDUFA extensions, largely driven by clinical and safety data submissions.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.